191 related articles for article (PubMed ID: 37215783)
1. TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma.
Lin J; Tang Z; Zhang C; Dong W; Liu Y; Huang H; Liu H; Huang J; Lin T; Chen X
Heliyon; 2023 May; 9(5):e16076. PubMed ID: 37215783
[TBL] [Abstract][Full Text] [Related]
2. Exploration of clinicopathological features of rearranged renal cell carcinoma and TFE3, TFEB, and ALK staining performance in renal entities.
Liu Y; Li X; Fan Y; Xu H; Gu Y; Dong L; Zhou L; Yang X; Wang C
Heliyon; 2023 Apr; 9(4):e15159. PubMed ID: 37089387
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
4. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
5. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population.
Qu Y; Gu C; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Feb; 6():21677. PubMed ID: 26880493
[TBL] [Abstract][Full Text] [Related]
7. A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3-rearranged renal cell carcinoma.
Li P; Xu Q; Chen M; Zhu J; Wang Y; Mumin MA; Huang K; Jiang Z; Liang H; Deng Q; Wang Z; Liao B; Chen W; Cao Y; Cao J; Luo J
Cancer Med; 2024 Mar; 13(5):e6813. PubMed ID: 38477529
[TBL] [Abstract][Full Text] [Related]
8. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients.
Sukov WR; Hodge JC; Lohse CM; Leibovich BC; Thompson RH; Pearce KE; Wiktor AE; Cheville JC
Am J Surg Pathol; 2012 May; 36(5):663-70. PubMed ID: 22498819
[TBL] [Abstract][Full Text] [Related]
9. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
11. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
12. Morphologic and Immunohistochemical Characteristics of Fluorescent In Situ Hybridization Confirmed TFE3-Gene Fusion Associated Renal Cell Carcinoma: A Single Institutional Cohort.
Akgul M; Saeed O; Levy D; Mann SA; Cheng L; Grignon DJ; Eble JN; Idrees MT
Am J Surg Pathol; 2020 Nov; 44(11):1450-1458. PubMed ID: 32701515
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma.
Dong X; Chen Y; Pan J; Ma W; Zhou P; Chen M; Guo H; Gan W
Front Oncol; 2022; 12():1017425. PubMed ID: 36276115
[TBL] [Abstract][Full Text] [Related]
14. A novel VCP::TFE3 gene fusion resulting from t(X;9)(p11.23;p13.3) chromosome translocation in TFE3 rearranged renal cancer cell carcinoma.
Kuentz MA; Blons H; Gimenez-Roqueplo AP; Just PA; Laurent-Puig P; Mejean A; Oudard S; Verkarre V
Genes Chromosomes Cancer; 2023 Jun; 62(6):361-366. PubMed ID: 36695651
[TBL] [Abstract][Full Text] [Related]
15. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
16. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
[TBL] [Abstract][Full Text] [Related]
17. Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.
Belsante M; Darwish O; Youssef R; Bagrodia A; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
Urol Oncol; 2014 Jan; 32(1):30.e23-8. PubMed ID: 23428539
[TBL] [Abstract][Full Text] [Related]
18. Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
Histopathology; 2017 Jul; 71(1):53-62. PubMed ID: 28199742
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.
Akgul M; Williamson SR; Ertoy D; Argani P; Gupta S; Caliò A; Reuter V; Tickoo S; Al-Ahmadie HA; Netto GJ; Hes O; Hirsch MS; Delahunt B; Mehra R; Skala S; Osunkoya AO; Harik L; Rao P; Sangoi AR; Nourieh M; Zynger DL; Smith SC; Nazeer T; Gumuskaya B; Kulac I; Khani F; Tretiakova MS; Vakar-Lopez F; Barkan G; Molinié V; Verkarre V; Rao Q; Kis L; Panizo A; Farzaneh T; Magers MJ; Sanfrancesco J; Perrino C; Gondim D; Araneta R; So JS; Ro JY; Wasco M; Hameed O; Lopez-Beltran A; Samaratunga H; Wobker SE; Melamed J; Cheng L; Idrees MT
J Clin Pathol; 2021 May; 74(5):291-299. PubMed ID: 33514585
[TBL] [Abstract][Full Text] [Related]
20. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
